VRTX·Vertex Pharmaceuticals Incorporated
VRTX|Analyst Targets
VRTX|Company Info
VRTX|Insider Trading
VRTX|Fundamentals
VRTX|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $0.01 | - | - |
| Q2'26 | $4.82 | $4.73 | -2.0% |
| Q1'26 | $4.39 | $4.47 | +1.7% |
| Q4'25 | $5.17 | $5.03 | -2.7% |
| Q3'25 | $4.58 | $4.80 | +4.9% |
| Q2'25 | $4.25 | $4.52 | +6.3% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $3.5B | - | - |
| Q2'26 | $3.3B | $3.3B | +1.1% |
| Q1'26 | $3.1B | $3.0B | -3.4% |
| Q4'25 | $3.2B | $3.2B | -1.5% |
| Q3'25 | - | $3.1B | - |
| Q2'25 | - | $3.0B | - |
VRTX|Monthly Returns
Market Data
VRTX Stock Snapshot
- Market cap
- 126.61B
- P/E ratio
- 28.7
- Day range
- $484.08 – $509.00
- News sentiment
- 65/100 · Bullish
- Analyst target
- $571.43 (+17.5%)
- Consensus
- Buy · 37 analysts
The technical read on VRTX is balanced, which usually means the market is waiting on a catalyst. The stock is liquid enough that positioning changes get absorbed without distorting the trend.
Behaviour On Record
What VRTX's own history says about today's numbers
- Realized volatility (21d)
- 14.4% 3rd pct
- Below its peak
- -8.8%
- vs 200-day average
- +7.4%
- Up days (1y)
- 49%
Vertex Pharmaceuticals Incorporated is currently running 14.4% annualised volatility over the last 21 sessions. Measured against VRTX's own 13 years of daily returns rather than a market-wide average, that is the 3rd percentile — unusually subdued by its own history, against a typical reading of 29.5%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
VRTX is trading -8.8% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -25.1%, and the deepest was -41.7% in 2016. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.
Price sits +7.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 52nd percentile — close to the gap it normally carries. Over the past year VRTX closed higher on 49% of sessions, and it is currently 1 session into a rising streak.
On October specifically: over 13 years of records, VRTX finished the month higher 8 of 13 times, with a median return of +2.5% and an average of -0.3%. Its strongest month historically has been June at +5.2% on average, its weakest September at -2.3%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: VRTX has opened more than 2% away from the prior close in 118 of 3,266 sessions (3.6% of the time), with the largest gaps running +48.0% and -7.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, VRTX moved an average of 3.5% in the session after earnings, closing higher 2 of those 3 times, with a median move of +2.6% and a largest of +7.7%.
All figures computed from 3,267 daily closes between 2013-10-14 and 2026-10-09, split-adjusted, recomputed daily. Percentiles are against VRTX's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of VRTX's sector?
Vertex Pharmaceuticals Incorporated sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving). Within its narrower Biotechnology industry group, VRTX ranks 13th of 15 tracked industries, lagging.
- Sector rank
- #4 of 12
- Sector state
- Improving
- Sector rotation score
- 73
- Industry rank
- #13 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on VRTX?
RBC Capital most recently reiterated its rating on Vertex Pharmaceuticals Incorporated to Outperform on Oct 8, 2026 with a price target of $576 (from $570). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- RBC Capital — Outperform
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
Peers & ETF holders
VRTX peers & ETF holders
BiotechnologyMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Capital World Investors | ▲ Buy | 26,115,014 | 10.03% | $12.97B | 2026-08-12 |
| BlackRock, Inc. | ▲ Buy | 24,109,373 | 9.26% | $11.98B | 2026-08-07 |
| Vanguard Group Inc | ▼ Sell | 24,105,823 | 9.26% | $10.93B | 2026-01-29 |
| Capital Research Global Investors | ▼ Sell | 19,490,637 | 7.48% | $9.68B | 2026-08-12 |
| Invesco Ltd. | ▲ Buy | 8,043,052 | 3.09% | $4.00B | 2026-08-14 |
| JPMorgan Chase & Co | ▼ Sell | 6,517,600 | 2.50% | $3.26B | 2026-08-12 |
| Geode Capital Management, LLC | ▼ Sell | 6,017,848 | 2.31% | $2.98B | 2026-08-12 |
| Loomis Sayles & Co L P | ▼ Sell | 3,920,953 | 1.51% | $1.95B | 2026-08-14 |
| Wellington Management Group LLP | ▲ Buy | 3,247,658 | 1.25% | $1.61B | 2026-08-14 |
| Morgan Stanley | ▲ Buy | 3,242,139 | 1.25% | $1.61B | 2026-08-13 |
| Bank of America Corp | ▲ Buy | 3,039,178 | 1.17% | $1.51B | 2026-08-14 |
| Norges Bank | ▼ Sell | 2,971,681 | 1.14% | $1.48B | 2026-08-12 |
| AllianceBernstein L.P. | ▼ Sell | 3,019,315 | 1.16% | $1.35B | 2026-08-14 |
| Northern Trust Corp | ▼ Sell | 2,486,478 | 0.95% | $1.24B | 2026-08-13 |
| Goldman Sachs Group Inc | ▲ Buy | 2,481,761 | 0.95% | $1.23B | 2026-08-14 |
| Janus Henderson Group plc | ▼ Sell | 2,131,527 | 0.82% | $951.79M | 2026-05-18 |
| FMR LLC (Fidelity) | ▼ Sell | 1,457,158 | 0.56% | $723.81M | 2026-08-13 |
| Wells Fargo & Company | ▲ Buy | 749,528 | 0.29% | $372.31M | 2026-08-14 |
| Citigroup Inc | ▲ Buy | 706,968 | 0.27% | $351.17M | 2026-08-03 |
| AQR Capital Management LLC | ▲ Buy | 616,170 | 0.24% | $305.00M | 2026-08-14 |
| Neuberger Berman Group LLC | ▲ Buy | 559,445 | 0.21% | $277.89M | 2026-08-13 |
| Marshall Wace, LLP | ▲ Buy | 543,897 | 0.21% | $270.17M | 2026-08-13 |
| Citadel Advisors LLC | ▲ Buy | 510,430 | 0.20% | $253.55M | 2026-09-02 |
| Millennium Management LLC | ▲ Buy | 468,410 | 0.18% | $232.67M | 2026-08-14 |
| Adage Capital Partners GP, L.L.C. | ▲ Buy | 393,964 | 0.15% | $195.69M | 2026-08-14 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| David J. Taylor | House | OH02 | ▼ Sell | $1K - $15K | 2026-08-26 | 2026-09-05 |
| Alan Armstrong | Senate | OK | ▲ Buy | $1K - $15K | 2026-03-27 | 2026-07-21 |
| David J. Taylor | House | OH02 | ▼ Sell | $1K - $15K | 2026-01-29 | 2026-02-02 |
| David J. Taylor | House | OH02 | ▲ Buy | $1K - $15K | 2025-08-07 | 2025-09-02 |
| Lisa McClain | House | MI09 | ▼ Sell | $1K - $15K | 2025-06-11 | 2025-08-13 |
| Lisa McClain | House | MI09 | ▼ Sell | $1K - $15K | 2025-06-10 | 2025-08-13 |
| Jefferson Shreve | House | IN06 | ▼ Sell | $15K - $50K | 2025-05-12 | 2025-06-22 |
| Byron Donalds | House | FL19 | ▼ Sell | $1K - $15K | 2025-03-20 | 2025-04-14 |
| Jefferson Shreve | House | IN06 | ▲ Buy | $15K - $50K | 2025-03-13 | 2025-04-11 |
| Jefferson Shreve | House | IN06 | ▲ Buy | $15K - $50K | 2025-02-24 | 2025-03-09 |
| Lisa McClain | House | MI09 | ▲ Buy | $1K - $15K | 2024-12-11 | 2025-08-13 |
| Julia Letlow | House | LA05 | ▲ Buy | $1K - $15K | 2024-10-23 | 2026-01-13 |
| Tommy Tuberville | Senate | AL | ▼ Sell | $1K - $15K | 2024-05-03 | 2026-08-05 |
| Tommy Tuberville | Senate | AL | ▲ Buy | $1K - $15K | 2022-10-06 | 2022-11-10 |
| John F. Reed | Senate | RI | ▼ Sell | $1K - $15K | 2019-02-04 | 2019-03-01 |
| John F. Reed | Senate | RI | ▼ Sell | $1K - $15K | 2018-03-09 | 2018-03-12 |
| John F. Reed | Senate | RI | ▼ Sell | $1K - $15K | 2015-05-13 | 2015-05-27 |